VRDN
Viridian Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Viridian Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No other changes.
No other changes.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Viridian Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Viridian Therapeutics, Inc.'s 6 closest co-movers, none share that code.
+15.53%
vs ±16.7% implied · ×0.93
shaded = implied · ▲▼ = realized
Viridian Therapeutics, Inc.
29.05
+3.90 · +15.51%
post 29.62 +1.96%
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $305.0M | 12.15% | +7.97% |
| BlackRockindex-like | $157.1M | 6.26% | +9.19% |
| Bellevue | $123.7M | 4.93% | +0.09% |
| Paradigm Biocapital | $123.5M | 4.92% | +113.53% |
| Kynam | $118.6M | 4.72% | +175.61% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $305.0M | 12.15% | +7.97% |
| BlackRockindex-like | $157.1M | 6.26% | +9.19% |
| Bellevue | $123.7M | 4.93% | +0.09% |
| Paradigm Biocapital | $123.5M | 4.92% | +113.53% |
| Kynam | $118.6M | 4.72% | +175.61% |
Expected move
No implied move.